Krystal Biotech (NASDAQ:KRYS) Posts Earnings Results, Beats Estimates By $0.23 EPS

Krystal Biotech (NASDAQ:KRYS) announced its quarterly earnings data on Monday. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23, Zacks reports. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same period in the previous year, the company posted $0.30 EPS. The firm’s revenue was up 116.4% on a year-over-year basis.

Krystal Biotech Stock Performance

KRYS opened at $181.10 on Wednesday. The stock’s 50 day moving average price is $158.48 and its 200-day moving average price is $175.30. Krystal Biotech has a one year low of $125.85 and a one year high of $219.34. The stock has a market cap of $5.22 billion, a price-to-earnings ratio of 60.57 and a beta of 0.84.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, February 19th. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Chardan Capital increased their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and a consensus price target of $210.00.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).